Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 3
2015 4
2016 4
2017 1
2018 3
2019 2
2020 1
2021 2
2023 1
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, Cartalat S, Tabouret E, Appay R, Bonneville-Levard A, Darlix A, Meyronet D, Barritault M, Gueyffier F, Remontet L, Maucort-Boulch D, Honnorat J, Dehais C, Ducray F; POLA Network. Esparragosa Vazquez I, et al. Neurooncol Adv. 2024 May 27;6(1):vdae078. doi: 10.1093/noajnl/vdae078. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38855053 Free PMC article.
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C; POLA Network. Picca A, et al. Eur J Cancer. 2024 May;202:114034. doi: 10.1016/j.ejca.2024.114034. Epub 2024 Mar 22. Eur J Cancer. 2024. PMID: 38537315 Clinical Trial.
TCF12 is mutated in anaplastic oligodendroglioma.
Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, Pastinen T, Hallout S, Figarella-Branger D, Dehais C, Idbaih A, Mokhtari K, Delattre JY, Huillard E, Mark Lathrop G, Sanson M, Houlston RS; POLA Network. Labreche K, et al. Nat Commun. 2015 Jun 12;6:7207. doi: 10.1038/ncomms8207. Nat Commun. 2015. PMID: 26068201 Free PMC article.
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network. Esparragosa Vazquez I, et al. Eur J Neurol. 2023 Sep;30(9):2879-2883. doi: 10.1111/ene.15873. Epub 2023 May 31. Eur J Neurol. 2023. PMID: 37204066
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M; POLA Network. Kacimi SEO, et al. J Clin Oncol. 2024 Oct 2:JCO2400049. doi: 10.1200/JCO.24.00049. Online ahead of print. J Clin Oncol. 2024. PMID: 39356975
Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L, Bronnimann C, Loiseau H, Frénel JS, Siegfried A, Seizeur R, Gauchotte G, Cappellen D, Carpentier C, Figarella-Branger D, Eimer S, Meyronet D, Ducray F; POLA network. Poetsch L, et al. J Neurooncol. 2021 Jan;151(2):279-286. doi: 10.1007/s11060-020-03662-x. Epub 2020 Nov 17. J Neurooncol. 2021. PMID: 33205355
The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches.
Billard P, Guerriau C, Carpentier C, Juillard F, Grandin N, Lomonte P, Kantapareddy P, Dufay N, Barritault M, Rimokh R, Verrelle P, Maucort-Boulch D, Figarella-Branger D, Ducray F, Dehais C, Charbonneau M, Meyronet D, Poncet DA; POLA network. Billard P, et al. Ann Oncol. 2021 Dec;32(12):1608-1617. doi: 10.1016/j.annonc.2021.09.004. Epub 2021 Oct 22. Ann Oncol. 2021. PMID: 34690007 Free article.
Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.
Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network. Rosenberg S, et al. Oncologist. 2018 Dec;23(12):1500-1510. doi: 10.1634/theoncologist.2017-0495. Epub 2018 Jul 17. Oncologist. 2018. PMID: 30018130 Free PMC article.
23 results